Viatris: A Contrarian Bet With Virtually No Downside

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline and global presence in key markets like the US, India, and China. The company's balance sheet is much improved, dividend yield is attractive at 5.26%, and valuation is extremely low versus sector peers. Upcoming FDA approvals and 11 key pipeline assets could drive rapid earnings growth and a major stock price re-rating toward $20 per share.